Picture Kentro Design Corporate and Web Design Berlin 600x60px
Organisation › Details

Adocia S.A.

Adocia is a biotech company specialized in the development of best-in-class drugs from the innovative formulation of certain already-approved therapeutic proteins. Adocia is specialized in insulin therapy and the treatment of the diabetic foot, one of the main complications of diabetes. Worldwide, more than 366 million individuals are currently suffering from diabetes (with a forecast of 552 million individuals by 2030, i.e. a 51% increase, reaching 70% in emerging countries). 15% of these patients will develop a foot ulcer during their lifetime. The markets targeted by Adocia represent more than USD20 billion (USD17 billion for insulin therapy and USD3 billion for diabetic foot ulcer healing). Through its BioChaperone® state-of-the-art technological platform, Adocia intends to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients, with the aim of making these medicines accessible to the broadest public. Adocia successfully completed two phases I and II studies on the formulation of a fast-acting human insulin and obtained promising phase I/II results on a diabetic foot ulcer-healing product. Furthermore, Adocia is developing a unique combination of fast-acting insulin and slow-acting insulin, for an optimal insulin therapy with one single product. To be a global leader for the formulation of therapeutic proteins Based on its experience and recognized know-how, Adocia has extended its activities to the formulation of monoclonal antibodies, which are gold standard molecules for the treatment of numerous chronic pathologies (oncology, inflammation, etc.). In this field, Adocia is engaged in collaborative programs with two major pharmaceutical companies. Adocia's therapeutic innovations aim at bringing solutions to a profoundly changing global pharmaceutical and economic context, characterized in particular by the increased prevalence and impact of the targeted pathologies, population growth and ageing, the need to control public health expenditures and increasing demand from emerging countries. Adocia is listed on the regulated market of Euronext in Paris (ISIN: FR0011184241, mnemo / Reuters / Bloomberg: ADOC, ADOC.PA, ADOC.FP) and its share included in the Next Biotech index. *


Period Start 2008-01-01 renamed
  Predecessor Proteins & Peptides Management – PPM
Products Industry BioChaperone® technology
  Industry 2 therapeutic protein
Persons Person Soula, Gérard (Adocia 201201 CEO + co-founder also founder of Flamel Technologies)
  Person 2 Danaguezian, Valérie (Adocia 201402 CFO)
Region Region Lyon
  Country France
  Street 115 Avenue Lacassagne
  City 69003 Lyon
  Tel +33-4-7261-0610
    Address record changed: 2018-07-24
Basic data Employees n. a.
  Currency EUR
  Annual sales 19,469,000 (revenu, operating (2017) 2017-12-31)
  Profit -8,550,000 (2017-12-31)
  Cash 55,885,000 (2018-06-30)
    * Document for �About Section�: Adocia S.A.. (12/9/13). "Press Release: Adocia Signs an Exclusive License on a Nanotechnology which Improves the Efficacy of Anti-tumoral Agents by Targeting Their Action into Tumors". Lyon.
Record changed: 2019-06-09


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Adocia S.A.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2019 Boston September 600x60px

» top